ArticleDermatology and therapy2026
Real-world Burden of Disease and Clinical Characteristics of Alopecia Areata Among Adults in Brazil: Results from a Cross-sectional Survey.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlopecia areata (AA) is an autoimmune disease characterized by patchy or complete nonscarring scalp hair loss (SHL) and is associated with significant psychosocial impacts. Current epidemiologic data on AA in Brazil are sparse, and advanced therapies may be difficult for patients to access. The objective of this study was to assess the real-world burden of disease and unmet need for patients with AA in Brazil.
methodsThis study used data from the Adelphi Real World AA II Brazil Disease Specific Programme™ (DSP), a cross-sectional survey conducted in Brazil (March-June 2024) incorporating retrospective data collection. Participating dermatologists completed patient record forms for their adult patients with AA. Variables assessed included patient demographics, clinical characteristics, treatment goals, prior and current treatments, and issues with current treatments, presented for the overall population, and stratified by extent of SHL and modality of health care access (public vs private health setting).
resultsOf the 341 patients included, 22 had 0% SHL, while 84, 95, 46, and 17 had 1-20%, 21-49%, 50-94%, and 95-100% SHL, respectively. More patients with 50-94% SHL had chronic AA versus other SHL groups, and patients with ≥ 50% SHL displayed more severe disease symptoms than those with < 50% SHL. The most common physician-reported goal is to improve current treatment to reduce SHL. Patients with < 50% SHL usually used non-systemic therapies (e.g., topical and intralesional treatments), whereas patients with ≥ 50% SHL reported using non-advanced systemic therapies. Significantly more patients in public settings received topical corticosteroids as their current treatment than in private settings (p = 0.0413).
conclusionThe burden of disease associated with AA is underrecognized in Brazil. To achieve the stated treatment goals, there is a need to expand access to advanced therapies that overcome the limitations of traditional therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.